Intelligent Digital Tools for Screening of Brain Connectivity and Dementia Risk Estimation in People Affected by Mild Cognitive Impairment

Status: Recruiting
Location: See all (5) locations...
Study Type: Observational
SUMMARY

Every three seconds someone in the world develops dementia. There are over 50 million people worldwide living with dementia and by 2030 this figure is expected to reach 82 million. Besides time-consuming patient investigations with low discriminative power for dementia risk, current treatment options focus on late symptom management. By screening brain connectivity and dementia risk estimation in people affected by mild cognitive impairment, the European Union (EU) funded AI-Mind project will open the door to extending the 'dementia-free' period by offering proper diagnosis and early intervention. AI-Mind will develop two artificial intelligence-based digital tools that will identify dysfunctional brain networks and assess dementia risk. Personalised patient reports will be generated, potentially opening new windows for intervention possibilities.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 60
Maximum Age: 75
Healthy Volunteers: f
View:

• Male and female aged between 60 and 75 years

• MCI diagnosis with a MMSE \>= 25

• or MCI diagnosis with MoCa \>= 17

Locations
Other Locations
Finland
Helsinki University Hospital
RECRUITING
Helsinki
Italy
Scientific Institute for Research, Hospitalization and Healthcare
RECRUITING
Roma
Università Cattolica del Sacro Cuore Campus di Roma
RECRUITING
Roma
Norway
Oslo University Hospital
RECRUITING
Oslo
Spain
Universidad Complutense de Madrid
RECRUITING
Madrid
Contact Information
Primary
Ira Haraldsen, PhD, MD
ira.haraldsen@icloud.com
92011533
Backup
Lina Plataniti, M.Sc.
linpla@ous-hf.no
45008425
Time Frame
Start Date: 2021-03-01
Estimated Completion Date: 2026-02-27
Participants
Target number of participants: 1000
Related Therapeutic Areas
Sponsors
Collaborators: Catholic University of the Sacred Heart, BrainSymph AS, Tallinna Ülikool, Det Norske Veritas, Helsinki University Central Hospital, Accelopment AG, Radboud University Medical Center, Neuroconnect Srl, Aalto University, Lurtis Rules S.L., Alzheimer Europe, Universidad Complutense de Madrid, IRCCS San Raffaele Roma, Oslo Metropolitan University
Leads: Oslo University Hospital

This content was sourced from clinicaltrials.gov